
News
Genzyme Releases
inv_genz_news_all Genzyme General News
| August 25, 2008 |
Genzyme Corporation and Medicines for Malaria Venture Announce New Collaboration with Advinus Therapeutics to Accelerate Discovery of Novel Therapies for Malaria | | August 6, 2008 |
Genzyme and Isis Begin Second Phase 3 Trial of Mipomersen | | July 23, 2008 |
Genzyme Reports Strong Second-Quarter Growth | | July 17, 2008 |
Genzyme Corporation and PTC Therapeutics Announce Collaboration on Small Molecule for Genetic Diseases | | June 24, 2008 |
Genzyme and Isis complete licensing of mipomersen | | June 17, 2008 |
Genzyme Files Applications for Approval of Mozobil in the United States and Europe | | June 2, 2008 |
Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients | | May 7, 2008 |
Preliminary Results from Phase 2 Genzyme Study | | April 25, 2008 |
FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen | | April 23, 2008 |
Genzyme Reports Strong First-Quarter Growth | | April 22, 2008 |
Genzyme to Build New R&D Center in Beijing | | April 21, 2008 |
Genzyme Provides Update on Myozyme® Manufacturing | | April 14, 2008 |
Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy | | March 19, 2008 |
Genzyme Withdraws Bioenvision’s European Filing of Evoltra® in Elderly AML Patients | | March 10, 2008 |
Genzyme Announces Presentation of New Positive Data on Carticel® | | March 6, 2008 |
Genzyme Launches Renvela® in the U.S. for Dialysis Patients | | February 13, 2008 |
Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year | | February 1, 2008 |
University of Massachusetts and Genzyme Launch Genzyme/UMass Scholars Program | | February 1, 2008 |
Genzyme and Isis Announce Hart-Scott-Rodino Approval Of Collaboration | | January 15, 2008 |
Genzyme Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Lung Cancer Diagnostic | | January 8, 2008 |
Genzyme Reports 21 Percent Increase in Fourth-Quarter Revenue | | January 7, 2008 |
Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen | | December 19, 2007 |
Genzyme Receives European CE Mark for Single-Treatment Synvisc-One™ | | December 17, 2007 |
Genzyme Announces FDA Approval of Thyrogen® For Use In Thyroid Cancer Ablation | | December 13, 2007 |
Genzyme Study of Myozyme® for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints | | December 5, 2007 |
Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML | | December 4, 2007 |
National Cancer Institute Study to Determine the Optimal Time for CLL Patients to Begin Treatment | | November 13, 2007 |
Genzyme Receives FDA Response Letter on Synvisc-One™ | | October 29, 2007 |
Epicel™ Wins Marketing Approval for Severe Burn Victims | | October 25, 2007 |
Genzyme and Sunway to Collaborate on Gene Therapy Program in China | | October 24, 2007 |
Genzyme Reports Strong Earnings Growth in Third Quarter | | October 23, 2007 |
Genzyme Launches Cholestagel® in Europe | | October 22, 2007 |
Bioenvision Shareholders Approve Acquisition by Genzyme Corporation | | October 22, 2007 |
FDA Approves Genzyme's Renvela™ for Dialysis Patients | | October 16, 2007 |
Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease | | October 15, 2007 |
Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis | | October 12, 2007 |
Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease | | October 12, 2007 |
Genzyme Recognized by Scientists as a Top Employer | | October 10, 2007 |
Delaware Court Approves Bioenvision, Genzyme Joint Petition | | October 10, 2007 |
Bioenvision and Genzyme File Petition in Delaware Court | | October 4, 2007 |
Genzyme Receives Approval to Market Elaprase® in Japan | | September 27, 2007 |
Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share | | September 26, 2007 |
Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis | | September 20, 2007 |
FDA Approves Expanded Labeling for Campath® to Include First-line Treatment for Leading Form of Adult Leukemia | | September 18, 2007 |
Genzyme Begins Major Expansion of Boston Manufacturing Facility | | August 29, 2007 |
Genzyme Announces Publication of DCOR Study in Kidney International | | July 23, 2007 |
Oswaldo Cruz Foundation and Genzyme Corporation Form Collaboration To Advance New Drugs for Neglected Diseases |
|
 |

|